Policy Brief
Medicare Coverage of Monoclonal Antibody Treatments for Alzheimer’s Disease: Key Issues from the CMS Proposed Coverage Decision
Published date
Overview
This Duke-Margolis issue brief summarizes the National Coverage Analysis (NCA) proposed decision memo issued by the Centers for Medicare & Medicaid Services (CMS) for the use of monoclonal antibodies (mAbs) to treat Alzheimer’s disease (AD). Our analysis focuses on key questions that would be valuable for CMS to clarify and that should be the subject of comments during the comment period that closes on February 10, 2022.
Duke-Margolis Authors
Nitzan Arad, LLM
Area Lead for Drug Pricing and Competition Policy
Beena Bhuiyan Khan, MSc
Research Director for Payment and Coverage Policy
Hannah Graunke, MPP
Senior Policy Analyst
Marianne Hamilton Lopez, PhD, MPA
Senior Research Director, Biomedical Innovation
Faculty Director of the Duke-Margolis Postdoctoral Associates & Affiliated Fellows Program
Adjunct Associate Professor
Senior Team Member
Margolis Core Faculty
Mark McClellan, MD, PhD
Director of the Duke-Margolis Institute for Health Policy
Robert J. Margolis, MD, Professor of Business, Medicine and Policy
Margolis Executive Core Faculty
